Unintentional pediatric poisonings before and during the COVID-19 pandemic: a population-based study
Myran DT, Gaudreault A, McCarthy SDS, Pugliese M, Tanuseputro P, Finkelstein Y. Am J Emerg Med. 2023; Dec 1 [Epub ahead of print].
Introduction — In the highly active antiretroviral therapy (HAART) era, HIV-related diarrhea remains common. There is no gold standard to measure diarrhea, making comparison across trials difficult. We conducted a systematic review to determine current research practice in measuring HIV-related diarrhea.
Method — MEDLINE was searched from 1980 to 2006 for clinical trials of treatment for HIV-related diarrhea. The following data were abstracted: type of trial, treatment studied, definition of diarrhea, and definition of improvement in diarrhea.
Results — We reviewed 384 articles; 46 met our inclusion criteria. Forty-two trials were prospective: 25 were open-label and 17 were controlled trials. Antimicrobials were studied most often (15 trials): octreotide was studied in 10 trials, and HAART in 5. Presence of diarrhea was most often defined by duration (33 trials, 72%), stool frequency (29 trials, 63%), and/or stool form (23 trials, 50%); often, more than one parameter was used. Stool frequency was used most often to measure diarrhea improvement (28 trials, 61%). Only one trial used a measure validated for HIV-related diarrhea.
Conclusion — Investigators rely on nonvalidated and disparate measures of HIV-related diarrhea. An easy-to-use, well-accepted, and valid tool to measure HIV-related diarrhea would enhance research in this field.
Tinmouth J, Kandel G, Tomlinson G, Walmsley S, Steinhart HA, Glazier R. HIV Clin Trials. 2007; 8(3):155-63.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.